NasdaqGS:QUREBiotechs
uniQure (QURE) Closed A Major Funding Round, Is The Pipeline Already Priced In?
uniQure (NasdaqGS:QURE) is back in focus after closing an upsized public offering that raised roughly US$259 million, following fresh clinical updates in Huntington’s disease and epilepsy that have sharpened attention on its gene therapy pipeline.
See our latest analysis for uniQure.
That funding news comes after a sharp re-rating in uniQure’s share price, which has risen strongly in recent months, with a 30 day share price return of 66.53% and a 1 year total shareholder return of 242.78%...